These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26183623)

  • 1. The role of the Pharmaceuticals and Medical Devices Agency and healthcare professionals in post-marketing safety.
    Mori K; Watanabe M; Horiuchi N; Tamura A; Kutsumi H
    Clin J Gastroenterol; 2014 Apr; 7(2):103-7. PubMed ID: 26183623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The Pharmaceuticals and Medical Devices Agency's Approach to Facilitate Risk Communication and Its Challenges].
    Kondo E; Torii M; Oba I; Okamoto M
    Yakugaku Zasshi; 2018; 138(3):307-314. PubMed ID: 29503421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development and evaluation of new drugs and medical devices in Japan--standpoint of regulatory agency].
    Maruyama H; Kondo T
    Brain Nerve; 2010 Mar; 62(3):263-8. PubMed ID: 20297731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Sponsor's Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit/Risk in Japan.
    Wolter KD; Kamatani A; Suzuki Y; Imaeda T; Dagher R; Safferman A; Junor R
    Pharmaceut Med; 2024 May; 38(3):217-224. PubMed ID: 38555545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Change of Reference to Post-Marketing Surveillance Based on the Sequence of Revising the Pharmaceutical Affairs Law.
    Takahashi H
    Yakushigaku Zasshi; 2016; 51(1):29-39. PubMed ID: 30183145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe Medical Devices Act: management guidance for hospital compliance with the new FDA requirements.
    Alder HC
    Hosp Technol Ser; 1993 Oct; 12(11):1-27. PubMed ID: 10129209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of safety-related regulatory actions by Japan's pharmaceutical regulatory agency.
    Ishiguro C; Misu T; Iwasa E; Izawa T
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1314-1320. PubMed ID: 28722235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Regulatory Science in the Review of Drugs and Medical Devices].
    Koide A
    Yakugaku Zasshi; 2016; 136(4):557-62. PubMed ID: 27040338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk communication with patients].
    Hirose M
    Yakugaku Zasshi; 2012; 132(5):561-2. PubMed ID: 22687691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reporting of Cardiovascular Medical Device Adverse Events to Pharmaceuticals and Medical Devices Agency, Japan.
    Handa N; Ishii K; Matsui Y; Ando Y
    EBioMedicine; 2015 Sep; 2(9):1211-6. PubMed ID: 26501120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marketing medical devices in Japan.
    Ohashi J
    Med Device Technol; 1998; 9(1):32-3, 36-7. PubMed ID: 10176143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA marketing claims, and the practitioner.
    Runner S
    J Evid Based Dent Pract; 2006 Mar; 6(1):19-23. PubMed ID: 17138391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmaceuticals and Medical Devices Agency (PMDA)'s new action for Pharmaceutical Affairs Consultation on Research and Development (R&D) Strategy].
    Masuyama K
    Yakugaku Zasshi; 2013; 133(2):183-6. PubMed ID: 23370511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Making Patient-focused Information Provision a Reality: One Company's Approach].
    Takemoto S
    Yakugaku Zasshi; 2018; 138(3):315-323. PubMed ID: 29503422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing evaluations help determine contraceptive safety, efficacy.
    Netw Res Triangle Park N C; 1988; 9(2):1-2, 7. PubMed ID: 12280950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Post-marketing drug safety measures for the attainment of safer and more effective use of drug].
    Kurokawa T
    Yakugaku Zasshi; 2011; 131(6):885-90. PubMed ID: 21628973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regulatory Science in Practice (Pharmaceuticals and Medical Devices Agency)].
    Hojo T
    Yakugaku Zasshi; 2017; 137(4):439-442. PubMed ID: 28381721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generating comparative evidence on new drugs and devices after approval.
    Cipriani A; Ioannidis JPA; Rothwell PM; Glasziou P; Li T; Hernandez AF; Tomlinson A; Simes J; Naci H
    Lancet; 2020 Mar; 395(10228):998-1010. PubMed ID: 32199487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory Frameworks for Gene and Cell Therapies in Japan.
    Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
    Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.